Preferred Label : Ruxolitinib Phosphate;
NCIt synonyms : (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile
Phosphate (1:1); 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-,
phosphate (1:1);
NCIt definition : The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase
(JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib
specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may
lead to a reduction in inflammation and an inhibition of cellular proliferation. The
JAK-STAT (signal transducer and activator of transcription) pathway plays a key role
in the signaling of many cytokines and growth factors and is involved in cellular
proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be
upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.;
UNII : 436LRU32H5;
InChIKey : JFMWPOCYMYGEDM-XFULWGLBSA-N;
CAS number : 1092939-17-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1092939-17-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Jakafi; Jakavi;
Molecule name : INCB-18424 Phosphate;
Chemical formula : C17H18N6H3O4P;
Origin ID : C97937;
UMLS CUI : C3247907;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Manual NTBT mappings (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_component_of_chemotherapy_regimen
- is_salt_form_of
http://www.has-sante.fr/portail/jcms/c_2658531/fr/jakavi
http://www.has-sante.fr/portail/jcms/c_2658531/fr/jakavi-ruxolitinib-inhibiteur-de-proteine-kinase
2016
false
France
French
Ruxolitinib Phosphate
Post essential thrombocythemia myelofibrosis
polycythemia vera
Post polycythemia vera myelofibrosis
thrombocythemia, essential
guidelines for drug use
Tyrosine Kinase Inhibitors
administration, oral
insurance, health, reimbursement
ruxolitinib
orphan drug production
treatment outcome
splenomegaly
ruxolitinib
janus kinases
ruxolitinib
primary myelofibrosis
evaluation of the transparency committee
pyrazoles
---
http://www.has-sante.fr/portail/jcms/c_2608680/fr/jakavi
2016
false
France
French
Ruxolitinib Phosphate
Post essential thrombocythemia myelofibrosis
Post polycythemia vera myelofibrosis
Tyrosine Kinase Inhibitors
administration, oral
insurance, health, reimbursement
ruxolitinib
orphan drug production
treatment outcome
splenomegaly
splenomegaly
ruxolitinib
ruxolitinib
janus kinases
ruxolitinib
ruxolitinib
primary myelofibrosis
evaluation of the transparency committee
pyrazoles
pyrazoles
---
